Natco Pharma Board Meeting on Aug 14 to Approve Q1 FY27 Unaudited Results

Natco Pharma Ltd has announced that its Board of Directors will convene on August 14, 2026. The primary agenda includes the consideration and approval of the Unaudited Financial Results for the quarter ended June 30, 2026. Additionally, the board will discuss the possibility of an interim dividend for the financial year 2026-27. The company also informed about the closure of the trading window for employees and connected persons from August 7 to August 16, 2026, reopening on August 17, 2026, in compliance with SEBI (Prohibition of Insider Trading) Regulations.